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Abstract
Alzheimer's disease (AD) is a neurodegenerative disease characterized by the accumulation of
intracellular and extracellular aggregates. According to the amyloid beta (Aβ) hypothesis,
amyloidosis occurring in the brain is a leading cause of neurodegeneration in AD. Defects in the
innate immune system may decrease the clearance of Aβ in the brain. Macrophages of most AD
patients do not transport Aβ into endosomes and lysosomes, and monocytes from AD patients do
not efficiently clear Aβ from AD brain. After stimulation with Aβ, mononuclear cells of normal
subjects display up-regulated transcription of MGAT3, which encodes β-1,4-mannosyl-glycoprotein
4-β-N-acetylglucosaminyltransferase, and Toll-like receptor (TLR) genes. Monocytes of AD patients
generally down-regulate these genes. A commonly used, naturally occurring material from a spice
that enhances certain key functions defective in cells of innate immunity of many AD patients has
shown epidemiologic rationale for use in AD treatment. Bisdemethoxycurcumin, a natural
curcumin, is a minor constituent of turmeric (curry), and it enhances phagocytosis and clearance
of Aβ in cells from most AD patients. We confirmed the effectiveness of a synthetic version of the
same compound. In mononuclear cells of most AD patients, bisdemethoxycurcumin enhanced
defective phagocytosis of Aβ and increased the transcription of MGAT3 and TLR genes. The potency
of bisdemethoxycurcumin as a highly purified compound in facilitating the clearance of Aβ in
mononuclear cells suggests the promise of enhanced effectiveness compared to curcuminoid
mixtures. Bisdemethoxycurcumin appears to enhance immune function in mononuclear cells of AD
patients and may provide a novel approach to AD immunotherapy.
Background
Alzheimer's disease (AD) is a major public health prob-
lem with a huge associated impact on individuals, fami-
lies, the healthcare system, and society. It is estimated that
as many as five million Americans currently suffer from
AD, and 50% of people over the age of 85 may have AD.
By the year 2050, the number of affected individuals in
the United States is expected to increase to over 13 million
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newborns is decreasing, the number of AD patients is
expected to increase dramatically as the population ages
[2]. AD is a heavy economic burden on individuals and
society, with an estimated annual cost of $100 billion in
the US alone. Current therapeutics show only limited
effectiveness in ameliorating the symptoms of AD and in
improving cognitive ability. Developing an effective ther-
apeutic to combat AD is therefore an immediate and
important challenge. Immune-based approaches to treat
Alzheimer's disease have shown some promise [3]. How-
ever, when applied to humans, immunization with amy-
loid beta (Aβ) resulted in development of adverse
inflammatory responses in a small fraction of the patients
tested [4]. Other small molecule immunostimulatory-
based strategies may be beneficial. Studies of natural com-
pounds that improve certain defects in innate immune
cells of some AD patients suggest a novel and safe thera-
peutic approach. For example, the natural product mix-
ture curcuminoids selectively enhanced Aβ phagocytosis
and gene transcription in blood cells of AD patients [5].
Characterization of the immunostimulatory properties,
and the different cellular and gene responses to curcu-
mins, may help to explain observed differences in Aβ
phagocytic response between AD and normal individuals,
and may eventually lead to diagnostic testing for disease
susceptibility or drug response.
Treatment of Alzheimer's disease
Treatment of AD remains a challenging goal due to our
incomplete understanding of its pathogenesis. AD is a
multi-component disease, and many biological and phys-
iological steps are involved in the eventual pathological
condition. Among other symptoms, the disease is associ-
ated with accumulation of neurofibrillary tangles and
amyloid plaques in brain tissue of affected individuals.
According to the 'Aβ hypothesis', the accumulation of
abnormally folded amyloid protein in the brain of AD
patients is a leading cause of neurodegeneration [6]. The
presence of excess Aβ may be a consequence of two possi-
ble pathways: an abnormal and toxic accumulation of Aβ;
and a defective detoxification mechanism that would
ordinarily clear accumulating Aβ. The mechanisms of
neurodegeneration resulting from abnormally folded pro-
teins such as Aβ remain poorly understood. With an
increasingly aging population, there exists an urgent need
for new and more effective therapeutic approaches [7].
Considerable interest exists in the role that the immune
system plays in AD pathology. Macrophages and micro-
glia are the innate immune cells responsible for clearance
of pathogens and waste products. It has been shown that
peripheral blood mononuclear cells (PBMCs) and macro-
phages of AD patients cross the blood-brain barrier, but
are defective in clearance of Aβ in neuritic plaques, and
over-express cyclooxygenase-2 and inducible nitric oxide
synthase [8]. Resident microglia in AD brain display
markers of phagocytic and inflammatory, but not pro-
phagocytic, genes [9]. However, in a transgenic mouse
model of AD, most microglia invading Aβ plaques are
bone marrow-derived, not resident microglia [10]. Thus,
the brains of AD patients and transgenic mice appear to
display microglial inflammatory responses, together with
defective Aβ clearance by blood-borne macrophages.
Defects in the innate immune system of AD patients may
therefore play a significant role in brain amyloidosis lead-
ing to brain inflammation and neurodegeneration.
Enhancement of a patient's innate immunity might repre-
sent a novel approach to AD therapy.
In addition to defects in both Aβ phagocytosis and clear-
ance of Aβ in AD brain sections, several molecular mark-
ers for monocytes and macrophages have been associated
with AD [11]. Unlike PBMCs from AD patients, PBMCs
from control subjects were found to up-regulate a number
of genes, including, among others, MGAT3 (β-1,4-man-
nosyl-glycoprotein-4-β-N-acetylglucosaminyltrans-
ferase), and Toll-like receptor (TLR) genes, which are
crucial for macrophage function. Evidence for a role of
mutated MGAT3 in transgenic mouse neuropathology has
been published [12], and we have reported suggestive evi-
dence for a correlation between defective MGAT3 expres-
sion and deficient Aβ phagocytosis [11]. Microarray
expression studies also identified several genes signifi-
cantly up-regulated in AD relative to control PBMCs in
response to Aβ exposure [11]. What is not clear from these
studies is whether normal expression of these genes is nec-
essary and sufficient for efficient Aβ clearance, or whether
other genes and pathways are involved. Also, given previ-
ous observations that macrophage Aβ phagocytosis is not
defective in all AD patients [5], it is unknown to what
extent naturally occurring polymorphisms in these impor-
tant genes may account for differences in Aβ uptake
between individuals. In this context, AD pathogenesis
may also involve other polymorphic proteins, including
amyloid precursor protein (APP), apolipoprotein E, and
other proteins in cellular mechanisms, including APP
processing [13], oxidative stress [14,15], and neuronal
apoptosis [16-18]. Clearly, a better understanding of the
genes responding to Aβ accumulation, and their involve-
ment in Aβ phagocytosis and clearance is needed.
Curcumins as AD therapeutics
Our studies have led us to examine the family of natural
products, curcumins, present in significant concentrations
in the spices turmeric and red curry, for which there exists
epidemiologic and aging-related rationale for use in AD
treatment [11]. There is evidence that consumption of
these natural compounds in various Asian populations is
associated with a protective effect against AD [19]. Also,Page 2 of 8
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Aβ in mouse models of AD [20]. However, curcuminoid
mixtures are composed of at least three curcumin com-
pounds. The three most prominent members of this class
of natural product include curcumin, demethoxycurcu-
min and bisdemethoxycurcumin (Figure 1). Curcumin is
the major material present in curcuminoids, and demeth-
oxycurcumin and bisdemethoxycurcumin are minor con-
stituents. A commonly observed ratio of
curcumin:demethoxycurcumin:bisemethoxycurcumin in
commercially available curcuminoid mixtures is
66:23:11. As described above, the curcuminoid mixture
was shown to possess significant immune-stimulating
properties. Based on commonly observed biological activ-
ities of natural products, we expected the curcuminoid
mixture to contain one compound that was more potent
than other materials present. We hypothesized that purifi-
cation of the most biologically potent material could offer
a potential drug discovery path for a new therapeutic
approach. We conducted a bio-directed purification of the
active component and showed that fractions enriched in
bisdemethoxycurcumin could improve the deficits in Aβ
uptake and clearance by innate immune cells from AD
patients (Figure 1) [11]. Bio-directed purification and iso-
lation of the most potent curcumin involved chemical
extraction and chromatographic purification, resulting in
increasingly pure compounds until the biological activity
was associated with one highly purified fraction. This
material was quite pure and liquid chromatography-mass
spectrometry showed that it was largely bisdemethoxycur-
cumin. Bisdemethoxycurcumin was examined for its abil-
ity to stimulate phagocytosis of Aβ in cells from control
and AD patients. Compared to the curcuminoid mixture,
and other curcumin components, bisdemethoxycurcumin
was the most potent compound at stimulating phagocyto-
sis of Aβ. The enhanced phagocytosis capabilities in the
presence of bisdemethoxycurcumin was also generally
associated with increases in expression of MGAT3 and TLR
genes in PBMCs from individuals testing positive for AD.
Based on mass spectrometric analysis that identified bis-
demethoxycurcumin as the most immuno-stimulatory
constituent in curcuminoid fractions, we verified the
immuno-enhancing effects of bisdemethoxycurcumin by
chemically synthesizing the same material and retesting it
alongside other highly purified synthetic and natural cur-
cumins. In all cases examined, bisdemethoxycurcumin
showed the most potent immuno-stimulatory activity
compared with other synthetic or natural curcumins or
demethoxycurcumin. Thus, these studies identified a nat-
urally occurring compound with the potential of at least
partially correcting cellular deficits associated with phago-
cytosis of Aβ of relevance to AD. Because bisdemethoxy-
curcumin has been used safely (albeit in a mixture of
other curcuminoids) for thousands of years, it is possible
that it may be directly useful as an agent to treat AD. How-
ever, safety studies may be required before the purified
compound is administered to humans. Regardless of the
advantages and disadvantages of bisdemethoxycurcumin
as an anti-AD agent, it can provide a lead molecule for the
elaboration of other compounds to be tested as immuno-
stimulating agents. The relative ease in synthesizing a vari-
ety of derivatives based on the bisdemethoxycurcumin
structure allows us to address whether close structural
analogs may afford more drug-like compounds and pro-
vide enhanced effectiveness and more promising drug
candidates.
Extracts containing curcuminoids are currently in clinical
use for a number of applications, including treatment of
Chemical structures of the principal constituents of curcu-minoidFigure 1
Chemical structures of the principal constituents of curcu-
minoid. Shown are the three predominant curcuminoids 
found in natural mixtures. Curcumin is commonly observed 
to be the major material, whereas demethoxycurcumin and 
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ulcerative colitis [21,22]. Curcuminoid extracts are also
available over-the-counter as herbal supplements. Rela-
tively large doses of curcuminoids are being used (that is,
2–8 g/day) because of limited bioavailability. Low bioa-
vailability is likely the result of rapid metabolism and low
gut penetration into the bloodstream. For example, curcu-
minoids compete for conjugation metabolic pathways
[23,24], oxidative metabolic pathways [25], and intestinal
efflux [26]. To improve clinical utility, and enhance bioa-
vailability, combination formulations involving the use
of agents that compete with metabolism and efflux mech-
anisms likely will be required to increase blood levels of
curcuminoids. Regardless, the apparent interaction with
oxidative and conjugative metabolic pathways suggests
that herb-drug interactions could pose a problem. The
approach to identify the most potent constituent in the
curcuminoid mixture could circumvent a number of the
bioavailability issues if the prominent curcumin compo-
nents are responsible for drug metabolism shortcomings.
Defective phagocytosis of Aβ in AD
AD amyloidosis may be related to defective brain clear-
ance of Aβ by monocytes and macrophages and differ-
ences in gene transcription [5]. As described before [11],
macrophages of most AD patients do not efficiently trans-
port Aβ into endosomes and lysosomes, and AD patient
monocytes do not efficiently clear Aβ from the AD brain
in vitro and in vivo, although they retain the ability to
phagocytose bacterial pathogens, for example, Escherichia
coli and Staphylococcus aureus. In contrast, macrophages of
normal subjects efficiently transport Aβ to endosomes
and lysosomes, and control monocytes clear Aβ in AD
brain sections. As described more fully in a later section,
treating PBMCs from control subjects with Aβ was associ-
ated with a relatively elevated expression of the gene
MGAT3, and genes encoding TLRs. In contrast, and in gen-
eral, monocytes from AD patients markedly down-regu-
late these same genes with the same treatment. These
levels of expression may correlate with the cells' ability to
take up and degrade Aβ, and experimental inhibition of
MGAT3 expression using small interfering RNA was
shown to interfere with Aβ clearance [11].
Endocytosis and intracellular transport of Aβ in 
macrophages
Fluorescein isothiocyanate (FITC)- Aβ phagocytosis by
macrophages from 42 control subjects, and 73 AD
patients, showed that macrophages of control subjects
usually (that is, approximately 90%) showed either excel-
lent or extremely efficient phagocytosis of soluble FITC-
Aβ within 24 hours. In contrast, a small fraction (15%) of
macrophages from AD patients showed extremely effi-
cient phagocytosis and the remainder displayed either
minimal surface uptake of FITC-Aβ (60%), or strong sur-
face localization but no intracellular uptake (25%). In
macrophages from control subjects, the intracellular
transport of Aβ was rapid. After one and two hour post-
exposure of macrophages from control subjects, FITC-Aβ
co-localized with the early endosomal marker Rab5. In
contrast, Rab5 staining and co-localization were minimal
in macrophages from AD patients. In macrophages from
control subjects, FITC-Aβ co-localized with the lysosomal
marker Lysotracker at each time interval (that is, 1, 48,
and 72 hours) post-exposure. In contrast, Aβ bound to the
cell surface of macrophages from AD patients, but did not
progress to lysosomes over a 72 hour period, and the lys-
osomes were poorly expressed. It appears that the mecha-
nism involving phagocytosis of bacteria is distinct from
the phagocytotic mechanism for Aβ.
Clearance of Aβ in Alzheimer brain sections by 
control and AD monocytes
As described previously, the phagocytic ability of mono-
cytes to digest Aβ in brain tissue was tested by co-culturing
human PBMCs with frozen sections of brain from patients
positively identified as having AD [11]. PBMCs from AD
patients and controls were co-cultured with frozen serial
sections of the frontal lobes of AD patients. The brain sec-
tion cultures were done under conditions that excluded
the role of antibodies in the clearance of brain Aβ. The
results were consistent: one-third of the monocytes exam-
ined from control subjects were saturated with fluores-
cently labeled Aβ after 2 days of co-culture, and 100%
were saturated after co-culturing for 4 days. In contrast,
less than one-quarter of the monocytes examined from
AD patients became saturated with Aβ, and the remaining
monocytes from AD patients were shrunken and aggre-
gated into clusters with staining that suggested monocyte
aggregation and Aβ release. The results suggested that
monocytes from control individuals were markedly more
effective at clearing Aβ when co-cultured with brain tissue
than monocytes from AD patients that were defective in
Aβ clearance [11].
Transcriptional dysregulation in PBMCs of AD 
patients
Whole-genome microarray analysis of mRNAs was carried
out to compare expression patterns in PBMCs of AD
patients and controls after overnight treatment with Aβ.
Compared to cells from AD patients, control cells up-reg-
ulated (>2.2-fold) the transcription of 35 genes and
expressed sequence tags (ESTs), including MGAT3 (327-
fold, P < 0.001), and the genes encoding fibronectin (FN1;
10.1-fold, P < 0.001), cholinergic receptor, muscarinic 4
(9.3-fold, P < 0.001), and 2'-5'-oligoadenylate synthetase
3 (OAS; 7.8-fold, P < 0.001), and down-regulated (>2-
fold) the transcription of an additional 35 genes or ESTs.
The most prominent transcriptional change in AD macro-
phages involved down-regulation of MGAT3 transcriptionPage 4 of 8
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N-acetylglucosaminyltransferase III (GlcNAc-TIII), which
transfers the bisecting N-acetylglucosamine to the core
mannose of complex N-glycans [27,28]. Another function
of GlcNAc-TIII is to stop further processing and elonga-
tion of N-glycans [29]. GlcNAc-TIII modulates cell inter-
actions, and potentiates α1 integrin-mediated
neuritogenesis [30]. Animals with truncated, inactive Glc-
NAc-TIII show neurological dysfunction [12]. Compared
to macrophages cultured from control individuals, macro-
phages cultured from AD patients are more susceptible to
apoptosis by Aβ [15,31]. However, over-expression of Glc-
NAc-TIII has been shown to protect cells against hydrogen
peroxide-induced apoptosis [32], and thus could help sta-
bilize AD macrophages during Aβ phagocytosis. Tran-
scriptional dysregulation of GlcNAc-TIII could also lead to
the altered N-glycosylation observed in AD [11]. In the
AD patients examined, the MGAT3 gene defect was
strongly associated with AD in the 60–80 years age group,
but not in subjects >80 years old. Also, the observed mar-
ginal association between decreased MGAT3 expression
and deficient Aβ phagocytosis (P = 0.069) supports the
idea that AD subjects >80 years old are distinct in so far as
phagocytosis is concerned.
To confirm the suggested transcriptional differences
observed between cells from AD patients and control sub-
jects, MGAT3 responses to Aβ in PBMCs of 18 AD
patients, and 9 control subjects, were investigated using
quantitative real-time PCR (qPCR) [11]. Cells from most
AD patients (12/18) showed down-regulation of MGAT3
(that is, ratio = 0.00001 to 0.99). The data were expressed
as a ratio of qPCR signal for the treated versus untreated
cells to account for variable baseline values between sub-
jects. The remaining samples from six AD patients
(including three AD patients >80 years old) up-regulated
MGAT3. In contrast, with the exception of two subjects
>80 years old, most samples from control individuals up-
regulated MGAT3 upon Aβ stimulation. Excluding the
>80 year-old population samples, in which greater varia-
tion was observed, the mean log MGAT3 RNA score of AD
patients (-1.747) and that of control subjects (+3.77) dif-
fered even more significantly (P = 0.001). Transcriptional
down-regulation in macrophages from AD patients of two
other genes noted in the microarray analysis, FN1 and
OAS, was also confirmed by qPCR. Co-treatment with bis-
demethoxycurcumin was associated with significant
increases in MGAT3 gene expression ratios in AD patient
cells.
Transcription of TLR genes in mononuclear cells 
of AD patients and control subjects
TLRs are crucial for macrophage function, and play an
important role in the detection of non-self by the innate
immune system. Activation of TLRs results in many func-
tional outcomes, including enhancement of apoptosis,
secretion of inflammatory cytokines, and direct antimi-
crobial activity [33]. Expression of TLR genes in response
to Aβ stimulation was examined using PBMCs of AD
patients and control subjects. A striking difference was
observed in TLR mRNA levels between PBMCs from con-
trol individuals and AD patients stimulated with Aβ.
Whereas control PBMCs exposed to Aβ up-regulated TLRs,
transcription of TLR1,TLR2,TLR3,TLR5,TLR8, and TLR10
was significantly down-regulated in similarly treated AD
cells. It is possible that the lower expression levels of TLR
genes in AD macrophages may be indicative of more glo-
bal innate immune defects beyond Aβ phagocytosis.
Expression profiling
The microarray and qPCR expression profiling identified
certain genes dysregulated in AD relative to control
PBMCs in response to Aβ treatment. We sought to identify
gene networks and biochemical pathways that may be sig-
nificantly up- or down-regulated in response to Aβ and
curcumins. Such gene pathway analyses may help identify
additional targets to understand the complexity of AD as
well as to find new potential targets for therapeutic inter-
vention. We used in silico tools from Ingenuity http://
www.ingenuity.com to identify pathways reportedly
involving MGAT3 that may be associated with the phago-
cytic and transcriptional responses dysregulated in AD
patient cells. Figure 2 depicts other gene products and
pathways for which interactions involving MGAT3 in var-
ious cell types, and under various conditions, have been
reported. Based on other proteins in the network, it is
interesting to speculate that MGAT3 in PBMCs may be
part of signaling pathways involving integrins plus Jun-
and MAP-kinases, and may contribute to leukocyte
extravasation into tissues, among other biological activi-
ties. Integrating the pathway information with microarray
data from differently treated cells will allow the assembly
and quantification of sets of genes that appear to be signif-
icantly over-represented among all known genes, and
determine if those genes are related biologically. In this
way, we can determine which metabolic, biochemical,
and transcriptional networks and pathways appear to be
responsive to Aβ and curcumin treatments. An important
objective of the pathway analyses will be to investigate the
roles of these, and their possibly novel activities, in the
context of Aβ phagocytosis in PBMCs. These analyses may
reveal other responding genes in addition to MGAT3 and
the TLR genes, possibly suggesting other cellular targets
that may be amenable to drug intervention.
Conclusion
Mononuclear cells from AD patients generally display
defective phagocytosis and transcriptional down-regula-
tion of certain key genes associated with phagocytosis.
Compared with age-matched mononuclear cells fromPage 5 of 8
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in innate immunity, including poor clearance of Aβ in
vitro and marked differences in gene transcription. After
Aβ stimulation of mononuclear cells from AD patients,
the most prominent transcriptional defect observed
involved down-regulation of MGAT3 and TLR genes.
MGAT3 may play a pivotal role in Aβ phagocytosis
because silencing of its transcription inhibited Aβ phago-
cytic function in monocytes from control individuals.
MGAT3 encodes an enzyme (GlcNAc-TIII) that modulates
cell interactions on a number of levels through N-glyco-
sylation of key proteins. It is possible that such an over-
arching enzymatic activity that is responsible for regulat-
ing a whole host of biological processes is a lynchpin in
the complex process of phagocytosis. Undoubtedly, an
array of coordinated events involving a large number of
proteins and receptors (many of which require N-glyco-
sylation for their biological activity) is required for Aβ
Putative biochemical pathways involving MGAT3Figure 2
Putative biochemical pathways involving MGAT3. Shown are pathways and gene networks with reported interactions involving 
MGAT3 under various conditions. Pathway analysis was performed using IPA tools (Ingenuity). Interactions are shown by lines: 
lines with arrows represent direct interactions and lines without arrows indicate binding only. Solid lines show reported direct 
interactions and broken lines show indirect interactions. Functions are indicated by shapes: enzymes (diamonds), cytokines 
(squares), kinases (triangles), transcription regulators (horizontal ovals), transmembrane receptors (vertical ovals), transport-
ers (trapezoids), complexes (concentric circles), and other (circles).
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role. Another gene family that is significantly down-regu-
lated in monocytes from AD patients stimulated with Aβ
is the TLR family of genes, members of which are crucial
for macrophage function. TLRs are pattern recognition
receptors, found on many cell types, including cells of the
innate immune system, that recognize conserved patho-
gen associated molecular patterns. Activation of TLRs
results in many functional outcomes, including enhance-
ment of apoptosis, secretion of inflammatory cytokines
and recognition of foreign materials, including bacteria.
Thus, TLRs perform a number of global functions for
innate cellular immunity. A defective TLR system is antic-
ipated to have far-reaching consequences for abnormal Aβ
phagocytosis as well as other functions in innate immu-
nity beyond Aβ phagocytosis.
Our studies led us to examine the natural product curcu-
mins, present in significant concentrations in the spices
turmeric and red curry, as there is an epidemiologic and
aging-related rationale for their use in AD treatment.
There is evidence that consumption of these natural com-
pounds in various Asian populations is associated with a
protective effect against AD [19]. Also, curcumin has been
shown to enhance brain clearance of Aβ in mouse models
of AD [20,34]. Offering the potential for a new therapeu-
tic approach, we identified a certain constituent of this
natural compound mixture (that is, bisdemethoxycurcu-
min) that can improve the defects in Aβ uptake and clear-
ance by the innate immune cells from AD patients [11].
Administration of bisdemethoxycurcumin to mononu-
clear cells from AD patients was generally associated with
enhancement of Aβ phagocytosis and an increase in
expression of MGAT3 and TLR genes in most AD patients.
Stimulation of mononuclear cells from control individu-
als with bisdemethoxycurcumin did not change Aβ
phagocytosis nor increase expression of MGAT3 or TLR
genes, suggesting that the curcuminoid bisdemethoxycur-
cumin was selectively up-regulating key genes in cells
from AD patients. We verified the effects of the immuno-
enhancing compound (bisdemethoxycurcumin) using a
chemically synthesized version. Thus, these studies led to
the identification of a natural compound with the poten-
tial of correcting cellular defects associated with AD. Syn-
thesis of more drug-like derivatives of
bisdemethoxycurcumin may allow us to address whether
structural analogs could provide enhanced effectiveness
and provide promising drug candidates. A more complete
knowledge of the gene expression profiles in innate
immune cells in response to biologically active com-
pounds will be invaluable toward understanding the
mechanisms of Aβ uptake, and for guiding rational drug
development efforts.
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